Jiangtao Gou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiangtao Gou has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Fengqing Zhang
Department of Psychological and Brain Sciences, Drexel University, Philadelphia, PA 19104, United States of America
9 shared publications - Ajit C. Tamhane
Northwestern University Evanston Illinois USA
7 shared publications - Dong Xi
Gilead Sciences Foster City California USA
3 shared publications - Cyrus R. Mehta
Cytel Corporation Cambridge MA USA
2 shared publications - Junrui Di
Pfizer, Inc., Cambridge, USA
2 shared publications - Oliver Y. Chen
Lausanne University Hospital
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 170, 108473
Sample size estimation for a flexible phase II oncology trial design using two dependent endpoints with nested response metrics
- 17 September 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 170, 108473
Open AccessSample size estimation for a flexible phase II oncology trial design using two dependent endpoints with nested response metrics
- 30 September 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (6) , e70040
Extending Multiple Testing With Unknown Test Dependency via the CoCo Test: With Applications to Cancer Studies
Multiple testing issues are common in clinical and scientific research, particularly in clinical trials involving multple endpoints. The central challenge lies in controlling the type I error rate (‐control). The behavior of multiple testing procedures for ‐control when the tests are independent or dependent but with a known joint distribution is relatively well known. When the joint distribution of test statistics is unknown, one can still guarantee the ‐control, if the positive dependency through stochastic ordering (PDS) condition is satisfied. Despite the frequent occurrence of unknown test dependency in multiple testing and the importance of the PDS condition in endorsing its validity, little do we know about how to verify this condition. Here, we develop a new nonparametric statistical test, called the CoCo test, based on ranked correlation coefficients and a simple, yet effective, algebraic arrangement of the Spearman's and Kendall's , that can validate the PDS condition, through which one can control for regardless of the prior knowledge of the dependency between test statistics. Simulation studies show that the CoCo test can faithfully detect the violation of the PDS condition or lack thereof. To further evaluate the efficacy of the CoCo test, we apply it to investigate three meta‐analyses. Our simulation studies and data analyses encourage one to evaluate the PDS condition during multiple testing, especially when one is uncertain about the relationship between tests, and the proposed CoCo test provides both methodological insights into and a technical device for doing so. An R package cocotest to implement the proposed methodology is available at CRAN.
- 30 September 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (6) , e70040
Extending Multiple Testing With Unknown Test Dependency via the CoCo Test: With Applications to Cancer Studies
Multiple testing issues are common in clinical and scientific research, particularly in clinical trials involving multple endpoints. The central challenge lies in controlling the type I error rate (‐control). The behavior of multiple testing procedures for ‐control when the tests are independent or dependent but with a known joint distribution is relatively well known. When the joint distribution of test statistics is unknown, one can still guarantee the ‐control, if the positive dependency through stochastic ordering (PDS) condition is satisfied. Despite the frequent occurrence of unknown test dependency in multiple testing and the importance of the PDS condition in endorsing its validity, little do we know about how to verify this condition. Here, we develop a new nonparametric statistical test, called the CoCo test, based on ranked correlation coefficients and a simple, yet effective, algebraic arrangement of the Spearman's and Kendall's , that can validate the PDS condition, through which one can control for regardless of the prior knowledge of the dependency between test statistics. Simulation studies show that the CoCo test can faithfully detect the violation of the PDS condition or lack thereof. To further evaluate the efficacy of the CoCo test, we apply it to investigate three meta‐analyses. Our simulation studies and data analyses encourage one to evaluate the PDS condition during multiple testing, especially when one is uncertain about the relationship between tests, and the proposed CoCo test provides both methodological insights into and a technical device for doing so. An R package cocotest to implement the proposed methodology is available at CRAN.
- Open Access
- 8 August 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 156, 108012
Using multiple biomarkers for patient enrichment in two-stage clinical designs
- 8 August 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 156, 108012
Open AccessUsing multiple biomarkers for patient enrichment in two-stage clinical designs
- 29 July 2025
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 18 (1) , 117-128
Improved Trimmed Weighted Hochberg Procedures With Two Endpoints and Sample Size Optimization
- 29 July 2025
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 18 (1) , 117-128
Improved Trimmed Weighted Hochberg Procedures With Two Endpoints and Sample Size Optimization
- 5 March 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (2) , e70004
Success and Futility Criteria for Accelerated Approval of Oncology Drugs
Project FrontRunner encourages development of cancer drugs for advanced or metastatic disease in an earlier clinical setting by promoting regulatory approaches such as the accelerated approval pathway. The FDA draft guideline proposes a one‐trial approach to combine accelerated approval and regular approval in a single trial to maintain efficiency. This article describes our idea of controlling Type I error for accelerated and regular approvals in the one‐trial approach. We introduce success and futility boundaries on p‐values for accelerated approval to create three outcomes: success, RA, and futility. If success, accelerated approval can be claimed for; for RA, only regular approval (RA) is considered; if futility, we stop the trial early for futility. For both success and RA, the endpoint for regular approval can be tested with no penalty on its significance level. The proposed approach is robust to all possible values of correlation between test statistics of the endpoints for accelerated and regular approvals. This framework is flexible to allow clinical trial teams to tailor success and futility boundaries to meet clinical and regulatory needs, while maintaining the overall Type I error control in the strong sense.
- 5 March 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (2) , e70004
Success and Futility Criteria for Accelerated Approval of Oncology Drugs
Project FrontRunner encourages development of cancer drugs for advanced or metastatic disease in an earlier clinical setting by promoting regulatory approaches such as the accelerated approval pathway. The FDA draft guideline proposes a one‐trial approach to combine accelerated approval and regular approval in a single trial to maintain efficiency. This article describes our idea of controlling Type I error for accelerated and regular approvals in the one‐trial approach. We introduce success and futility boundaries on p‐values for accelerated approval to create three outcomes: success, RA, and futility. If success, accelerated approval can be claimed for; for RA, only regular approval (RA) is considered; if futility, we stop the trial early for futility. For both success and RA, the endpoint for regular approval can be tested with no penalty on its significance level. The proposed approach is robust to all possible values of correlation between test statistics of the endpoints for accelerated and regular approvals. This framework is flexible to allow clinical trial teams to tailor success and futility boundaries to meet clinical and regulatory needs, while maintaining the overall Type I error control in the strong sense.
- Open Access
- 23 January 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (3-4) , e10346
Testing One Primary and Two Secondary Endpoints in a Two‐Stage Group Sequential Trial With Extensions
We study the problem of testing multiple secondary endpoints conditional on a primary endpoint being significant in a two‐stage group sequential procedure, focusing on two secondary endpoints. This extends our previous work with one secondary endpoint. The test for the secondary null hypotheses is a closed procedure. Application of the Bonferroni test for testing the intersection of the secondary hypotheses results in the Holm procedure while application of the Simes test results in the Hochberg procedure. The focus of the present paper is on developing normal theory analogs of the abovementioned ‐value based tests that take into account (i) the gatekeeping effect of the test on the primary endpoint and (ii) correlations between the endpoints. The normal theory boundaries are determined by finding the least favorable configuration of the correlations and so their knowledge is not needed to apply these procedures. The ‐value based procedures are easy to apply but they are less powerful than their normal theory analogs because they do not take into account the correlations between the endpoints and the gatekeeping effect referred to above. On the other hand, the normal theory procedures are restricted to two secondary endpoints and two stages mainly because of computational difficulties with more than two secondary endpoints and stages. Comparisons between the two types of procedures are given in terms of secondary powers. The sensitivity of the secondary type I error rate and power to unequal information times is studied. Numerical examples and a real case study illustrate the procedures.
- 23 January 2025
- Published by Wiley in Statistics in Medicine
- Vol. 44 (3-4) , e10346
Open AccessTesting One Primary and Two Secondary Endpoints in a Two‐Stage Group Sequential Trial With Extensions
We study the problem of testing multiple secondary endpoints conditional on a primary endpoint being significant in a two‐stage group sequential procedure, focusing on two secondary endpoints. This extends our previous work with one secondary endpoint. The test for the secondary null hypotheses is a closed procedure. Application of the Bonferroni test for testing the intersection of the secondary hypotheses results in the Holm procedure while application of the Simes test results in the Hochberg procedure. The focus of the present paper is on developing normal theory analogs of the abovementioned ‐value based tests that take into account (i) the gatekeeping effect of the test on the primary endpoint and (ii) correlations between the endpoints. The normal theory boundaries are determined by finding the least favorable configuration of the correlations and so their knowledge is not needed to apply these procedures. The ‐value based procedures are easy to apply but they are less powerful than their normal theory analogs because they do not take into account the correlations between the endpoints and the gatekeeping effect referred to above. On the other hand, the normal theory procedures are restricted to two secondary endpoints and two stages mainly because of computational difficulties with more than two secondary endpoints and stages. Comparisons between the two types of procedures are given in terms of secondary powers. The sensitivity of the secondary type I error rate and power to unequal information times is studied. Numerical examples and a real case study illustrate the procedures.
- 20 September 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (28) , 5229-5246
Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment
Graphical approach provides a useful framework for multiplicity adjustment in clinical trials with multiple endpoints. When designing a graphical approach, initial weight and transition probability for the endpoints are often assigned based on clinical importance. For example, practitioners may prefer putting more weights on some primary endpoints. The clinical preference can be formulated as a constrain in the sample size optimization problem. However, there has been a lack of theoretical guidance on how to specify initial weight and transition probability in a graphical approach to meet the clinical preference but at the same time to minimize the sample size needed for a power requirement. To fill this gap, we propose statistical methods to optimize sample size over initial weight and transition probability in a graphical approach under a common setting, which is to use marginal power for each endpoint in a trial design. Importantly, we prove that some of the commonly used graphical approaches such as putting all initial weights on one endpoint are suboptimal. Our methods are flexible, which can be used for both single‐arm trials and randomized controlled trials with either continuous or binary or mixed types of endpoints. Additionally, we prove the existence of optimal solution where all marginal powers are placed exactly at the prespecified values, assuming continuity. Two hypothetical clinical trial designs are presented to illustrate the application of our methods under different scenarios. Results are first presented for a design with two endpoints and are further generalized to three or more endpoints. Our findings are helpful to guide the design of a graphical approach and the sample size calculation in clinical trials.
- 20 September 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (28) , 5229-5246
Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment
Graphical approach provides a useful framework for multiplicity adjustment in clinical trials with multiple endpoints. When designing a graphical approach, initial weight and transition probability for the endpoints are often assigned based on clinical importance. For example, practitioners may prefer putting more weights on some primary endpoints. The clinical preference can be formulated as a constrain in the sample size optimization problem. However, there has been a lack of theoretical guidance on how to specify initial weight and transition probability in a graphical approach to meet the clinical preference but at the same time to minimize the sample size needed for a power requirement. To fill this gap, we propose statistical methods to optimize sample size over initial weight and transition probability in a graphical approach under a common setting, which is to use marginal power for each endpoint in a trial design. Importantly, we prove that some of the commonly used graphical approaches such as putting all initial weights on one endpoint are suboptimal. Our methods are flexible, which can be used for both single‐arm trials and randomized controlled trials with either continuous or binary or mixed types of endpoints. Additionally, we prove the existence of optimal solution where all marginal powers are placed exactly at the prespecified values, assuming continuity. Two hypothetical clinical trial designs are presented to illustrate the application of our methods under different scenarios. Results are first presented for a design with two endpoints and are further generalized to three or more endpoints. Our findings are helpful to guide the design of a graphical approach and the sample size calculation in clinical trials.
- 13 April 2023
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 16 (1) , 64-70
A Test of the Dependence Assumptions for the Simes-Test-based Multiple Test Procedures
The Hochberg procedure is known to be more powerful than the Bonferroni method but the test statistics need to satisfy certain dependence conditions. Due to the lack of validation of the positive dependence assumption in the Hochberg procedure, the US Food and Drug Administration guidance on multiple endpoints in clinical trials provides conservative recommendations on the Hochberg procedure, and limits its application on a small set of standard test statistics. Based on the demand of using the Hochberg procedure in a more flexible way, we develop a test to validate the dependence assumption in the Hochberg procedure and Benjamini-Hochberg procedure. A simulation study is conducted for power analysis, and a case study in metastatic breast cancer is included to illustrate how the proposed test can be applied to validating the dependence type between the progression-free survival and overall survival.
- 13 April 2023
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 16 (1) , 64-70
A Test of the Dependence Assumptions for the Simes-Test-based Multiple Test Procedures
The Hochberg procedure is known to be more powerful than the Bonferroni method but the test statistics need to satisfy certain dependence conditions. Due to the lack of validation of the positive dependence assumption in the Hochberg procedure, the US Food and Drug Administration guidance on multiple endpoints in clinical trials provides conservative recommendations on the Hochberg procedure, and limits its application on a small set of standard test statistics. Based on the demand of using the Hochberg procedure in a more flexible way, we develop a test to validate the dependence assumption in the Hochberg procedure and Benjamini-Hochberg procedure. A simulation study is conducted for power analysis, and a case study in metastatic breast cancer is included to illustrate how the proposed test can be applied to validating the dependence type between the progression-free survival and overall survival.
- 9 February 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (1) , 90-110
Reverse graphical approaches for multiple test procedures
The graphical approach has been proposed as a general framework for clinical trial designs involving multiple hypotheses, where decisions are made only based on the observed marginal -values. The graphical approach starts from a graph that includes all hypotheses as vertices and gradually removes some vertices when their corresponding hypotheses are rejected. In this paper, we propose a reverse graphical approach, which starts from a set of singleton graphs and gradually adds vertices into graphs until rejection of a set of hypotheses is made. Proofs of familywise error rate control are provided. A simulation study is conducted for statistical power analysis, and a case study is included to illustrate how the proposed approach can be applied to clinical studies.- 9 February 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (1) , 90-110
Reverse graphical approaches for multiple test procedures
The graphical approach has been proposed as a general framework for clinical trial designs involving multiple hypotheses, where decisions are made only based on the observed marginal -values. The graphical approach starts from a graph that includes all hypotheses as vertices and gradually removes some vertices when their corresponding hypotheses are rejected. In this paper, we propose a reverse graphical approach, which starts from a set of singleton graphs and gradually adds vertices into graphs until rejection of a set of hypotheses is made. Proofs of familywise error rate control are provided. A simulation study is conducted for statistical power analysis, and a case study is included to illustrate how the proposed approach can be applied to clinical studies.- 6 January 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 33 (5) , 596-610
On dependence assumption in p-value based multiple test procedures
There are various multiple comparison procedures used in confirmatory clinical studies and exploratory research for multiplicity adjustment. Among them are the Hochberg and Benjamini-Hochberg procedures. A common misconception is that these procedures control the type I error rate properly if the test statistics are independent or positively correlated. In fact, a much stronger positive dependence assumption needs to be satisfied to guarantee the type I error rate control. We give a comprehensive review of the dependence conditions used in multiple testing procedures. We show that a weaker positive dependence assumption may result an inflation of type I error rate by a factor of 2 and discuss the type I error rate control under certain negative dependence conditions.
- 6 January 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 33 (5) , 596-610
On dependence assumption in p-value based multiple test procedures
There are various multiple comparison procedures used in confirmatory clinical studies and exploratory research for multiplicity adjustment. Among them are the Hochberg and Benjamini-Hochberg procedures. A common misconception is that these procedures control the type I error rate properly if the test statistics are independent or positively correlated. In fact, a much stronger positive dependence assumption needs to be satisfied to guarantee the type I error rate control. We give a comprehensive review of the dependence conditions used in multiple testing procedures. We show that a weaker positive dependence assumption may result an inflation of type I error rate by a factor of 2 and discuss the type I error rate control under certain negative dependence conditions.